 |
The CARE trial
included 576 (14%) women, whose mean HDL-C at baseline was 45 mg/dl, which is borderline
low for women. Pravastatin significantly reduced combined coronary events (coronary death,
nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty [PTCA], and
coronary artery bypass grafting [CABG]) by 45% and PTCA by 48%; reductions in CABG and
stroke were substantial but were not statistically significant. Reference:
Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye
LA, Rouleau JL, Pfeffer MA, Braunwald E, for the CARE investigators. Effect of pravastatin
on cardiovascular events in women after myocardial infarction: the Cholesterol and
Recurrent Events (CARE) trial. J Am Coll Cardiol 1998;32:140-146. |
